Inclusion Criteria:

- Subjects with non-myeloid malignancy

- At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless
of schedule

- Hemoglobin concentration less than 11.0 g/dL within 24 hours before randomization

- Adequate serum folate and vitamin B12

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

- Of legal age at the time written informed consent is obtained

Exclusion Criteria:

- Known history of seizure disorder

- Known primary hematologic disorder causing anemia other than non-myeloid malignancies

- Unstable/uncontrolled cardiac condition

- Clinically significant inflammatory disease

- Other diagnoses not related to the cancer which can cause anemia

- Inadequate renal and liver function

- Iron deficiency

- Known positive test for HIV infection

- Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO

- Received more than 2 red blood cell (RBC) transfusions within 4 weeks of
randomization; or any RBC transfusion within 14 days before randomization; or any
planned RBC transfusion between randomization and study day 1

- Received any erythropoietic therapy within 4 weeks of study day 1 or any planned
erythropoietic therapy between randomization and study day 1

- Other investigational procedures

- Currently enrolled in or has not yet completed at least 30 days since ending other
investigational device or drug trial(s), or subject receiving other investigational
agent(s)

- Pregnant or breast feeding

- Not using adequate contraceptive precautions

- Previously randomized into this study

- Known hypersensitivity to any products to be administered

- Concerns for subject's compliance